Collegium Pharmaceutical Inc
COLL
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.09B
Close$
$17.40
44% downside
Current Fair Value
44% downsideOvervalued by 44% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.09 Billion |
|---|---|
| Enterprise Value | $1.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.98 |
| Beta | 0.76 |
| Outstanding Shares | 32,087,472 |
Return
| Return on Equity | 23.99% |
|---|---|
| Return on Assets | 4.54% |
| Return on Invested Capital | 21.81% |
Valuation & Multiples
| P/E Ratio | 14.39 |
|---|---|
| PEG | 2.88 |
| Price to Sales | 1.29 |
| Price to Book Ratio | 3.45 |
| Enterprise Value to Revenue | 2.05 |
| Enterprise Value to EBIT | 6.14 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.5 |
| Debt to Equity | 2.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$1.69
Average shareholder expectationRevenue Estimate
$186.75 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$1.68
Average shareholder expectationRevenue Estimate
$201.41 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 118.86%▲ 1.25% |
|---|---|
| Total Invested | $1.25B▼ 27.46% |
| Investors Holding | 264▼ 15.00% |
ESG Score
No data
About Collegium Pharmaceutical Inc
CEO: Joseph Ciaffoni